Table 1 Studies which evaluated sacubitril/valsartan in the context of CTRCD. Table 1 Studies which evaluated sacubitril/valsartan in the context of CTRCD. Table 1 Studies which evaluated sacubitril/valsartan in the context of CTRCD. Table 1 Studies which evaluated sacubitril/valsartan in the context of CTRCD. Table 1 Studies which evaluated sacubitril/valsartan in the context of CTRCD.
Studies (references) Study types No. of patients Offending agents Follow-up End points
Sheppard et al. (37) Retrospective descriptive case study Two Anthracycline Six months Fair recovery of NYHA functional class, normalization of NT-proBNP concentration, no re-hospitalization for heart failure
Canale et al. (38) Prospective descriptive case study Four Anthracycline or carfilzomib One/Six/Twelve months Fair recovery of NYHA functional class, reverse remodeling of ventricular size, no re-hospitalization for heart failure
Frey et al. (39) Pilot study Twenty-one Antineoplastic agents and radiation Twelve months Significant improvement in NYHA functional class and NT-proBNP levels
Martín-Garcia et al. (40) Retrospective multicenter registry study Sixty-seven Wide-ranging antineoplastic agents or (and) thoracic radiotherapy Median: 4.6 [IQR 1-11] months Fair recovery of NYHA functional class, NT-proBNP concentration, echocardiographic functional and structural parameters
Renato et al. (41) Descriptive case study Two Anthracycline Four/Twenty-four months Fair recovery of NYHA functional class, NT-proBNP concentration, echocardiographic functional and structural parameters
Ana et al. (42) Retrospective multicentre registry study Ten Wide-ranging antineoplastic agents For at least 3 months Fair recovery of NYHA functional class, NT-proBNP concentration, LVEF and LV remodelling
Gregorietti et al. (43) Prospective registry study Twenty-eight Anthracycline or with anti-HER2 therapies Median: Twenty months Fair recovery of NYHA functional class, NT-proBNP concentration, echocardiographic functional and structural parameters
Xi et al. (47) Descriptive case study One Anthracycline and trastuzumab Four months Normalization of LVEF and NT-proBNP concentration
Lupi et al. (48) Descriptive case study One Rituximab Twelve months Durable improvement of symptoms, LVEF and NT-proBNP concentration
Wu et al. (49) Descriptive case study One Immuno-checkpoint inhibitor Two months Certain recovery of NYHA functional class, cardiac functional and structural parameters
PRADA II trial (50) A randomized, double blind, multi-center, clinical trial 214 patients (neo-)adjuvant chemotherapy with epirubicin independently of additional trastuzumab/pertuzumab treatment At baseline, at end of anthracycline treatment and following 18 months after enrolment The primary outcome: LVEF by CMR from baseline to 18 months. Secondary outcomes: change in LV function by global longitudinal strain by CMR and echocardiography and change in circulating cardiac troponin concentrations.
Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left ventricular ejection fraction; CMR, cardiac magnetic resonance. Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left ventricular ejection fraction; CMR, cardiac magnetic resonance. Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left ventricular ejection fraction; CMR, cardiac magnetic resonance. Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left ventricular ejection fraction; CMR, cardiac magnetic resonance. Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left ventricular ejection fraction; CMR, cardiac magnetic resonance. Abbreviations: NYHA, new york heart association; NT-proBNP, N-terminal pro brain natriuretic peptide; IQR, inter quartile range; LVEF, left ventricular ejection fraction; CMR, cardiac magnetic resonance.